Company Profiles

driven by the PitchBook Platform

NGM Biopharmaceuticals

NGM Biopharmaceuticals
2008 FOUNDED
PRIVATE STATUS
101-200 EMPLOYEES
Series E LATEST DEAL TYPE
$200M LATEST DEAL AMOUNT
9 INVESTORS
Description

Operator of a biopharmaceutical platform intended to focus on the treatment of diabetes and obesity. The company's biopharmaceutical platform identify and validate targets that impact the underlying etiology of metabolic, cardio-metabolic and liver diseases as well as focuses on elucidating the biology of hormones, cell receptors and associated ligands, enabling patients to get quick recovery from diabetes and obesity.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Primary Office
333 Oyster Point Boulevard
South San Francisco, CA 94080
United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore NGM Biopharmaceuticals’s full profile, request a free trial.

NGM Biopharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series E) 26-Mar-2015 $200M 00000 00000 Completed Generating Revenue
4. Later Stage VC (Series D) 23-Feb-2015 000.00 00000 00000 Completed Generating Revenue
3. Later Stage VC (Series C) 18-Jul-2013 0000 00000 00000 Completed Startup
2. Early Stage VC (Series B) 07-Nov-2011 $55.7M $82.3M 00000 Completed Startup
1. Early Stage VC (Series A) 18-Dec-2009 $26.6M $26.6M 000.00 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

NGM Biopharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series E 00,000,000 00.000000 00 00 00 00 00 000
Series D 00,000,000 00.000000 00 00 00 00 00 00.000
Series C 00,000,000 00.000000 00 00 00 00 00 00.000
Series B 22,155,600 $0.001000 8% $2.5 $2.5 1x $2.5 18.81%
Series A 26,589,274 $0.001000 8% $1 $1 1x $1 22.58%
To view this company’s complete Cap Table, request access »

NGM Biopharmaceuticals Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Merck Capital Ventures Corporate Venture Capital Minority 000 0000 000000 0
Solon Mack Capital Family Office Minority 000 0000 000000 0
Takeda Ventures Corporate Venture Capital Minority 000 0000 000000 0
Topspin Venture Venture Capital Minority 000 0000 000000 0
Individual Investor Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

NGM Biopharmaceuticals Executive Team (19)

Name Title Board
Seat
Contact
Info
William Rieflin JD Chief Executive Officer & Board Member
Jin-Long Chen Ph.D Founder, Chief Scientific Officer & Board Member
Jeff Jonker President
David Woodhouse Chief Financial Officer
Aetna Trombley Ph.D Vice President, Business Development & Chief Operating Officer

2 Former Executives

You’re viewing 5 of 19 executives. Get the full list »

NGM Biopharmaceuticals Board Members (9)

Name Representing Role Since Contact
Info
Arthur Levinson Ph.D Self Board Member 000 0000
David Goeddel Ph.D The Column Group Chairman 000 0000
David Schnell MD Prospect Venture Partners Board Member 000 0000
Jin-Long Chen Ph.D NGM Biopharmaceuticals Founder, Chief Scientific Officer & Board Member 000 0000
Joseph Goldstein MD Self Chairman 000 0000
You’re viewing 5 of 9 board members. Get the full list »
Questions or concerns about this profile? Reach out to website-support@pitchbook.com